

# Portfolio strategies of cytotoxic drugs – current topics of regulatory economy

**Claudia Keupp**


**13th DGRA Annual Congress 2011**

## Market situation and trend for oncological drugs

— **Special market with a high growth potential**

— **Market growth for**

- „Classic“ cytotoxic drugs
- Targeted therapies




# Portfolio strategies for cytotoxic drugs

## — Analysis of the actual situation


- BCG-Matrix

## — Management of the portfolio



## Analysis of the actual situation

- **Self-evaluation of the manufacturer**
- **Competitor analysis**





---

## Management of the portfolio

- **Cost minimisation / optimisation**
- **Product differentiation**
- **Market focus / market expansion**



---

## Development and authorisation of new products

### — **Centralised Procedure (Reg. (EC) 726/2004)**

- **Mandatory for anti-cancer products**

### — **Special procedures within the Centralised Procedure**

- **Accelerated assessment procedure**
- **Conditional approval**
- **Approval under exceptional circumstances**
- **Authorisation as orphan drug**
- **Compassionate use**



## Management of profitable existing products

- **Renewals**
- **Variations**
- **Off-label use**



---

## Management of non-profitable existing products

### — **Out-licensing**


- **Loss of market share**
- **Portfolio changed**

### — **Implication of the „Sunset Clause“**

- **Future product differentiation**

## Decision Analysis: Authorisation of a new cytotoxic drug

- **New drug: capsule with Pt-containing API**
- **Efficacy against**
  - **Main cancer types: lung cancer, breast cancer**
  - **Rare cancer types: renal cell carcinoma, cervical carcinoma**
- **Possible marketing authorisation applications**
  - **For main cancer types: Accelerated Approval**
  - **For rare cancer types: Conditional Approval**  
**Orphan Drug Designation**





---

## Decision Analysis: Authorisation of a new cytotoxic drug

### — **Strategies:**

- „Push marketing-strategy“: first MA for main indication
- „Pull marketing-strategy“: first MA for rare indication

### — **Best balanced choice:**

- First MA for rare indication „renal cell carcinoma“
- Then MAs for main indications „lung cancer“ and „breast cancer“



---

Herzlichen Dank

**Herrn Dr. J. Hofer  
(Exdra GmbH)**

**Herrn H. A. Jopp  
(Jopp & Wilkens)**

**Heraeus GmbH  
Hanau**